[go: up one dir, main page]

PE20140860A1 - Compuestos de pirazol como antagonistas de crth2 - Google Patents

Compuestos de pirazol como antagonistas de crth2

Info

Publication number
PE20140860A1
PE20140860A1 PE2013001586A PE2013001586A PE20140860A1 PE 20140860 A1 PE20140860 A1 PE 20140860A1 PE 2013001586 A PE2013001586 A PE 2013001586A PE 2013001586 A PE2013001586 A PE 2013001586A PE 20140860 A1 PE20140860 A1 PE 20140860A1
Authority
PE
Peru
Prior art keywords
independently
compounds
benzyl
carbonyl
fluoro
Prior art date
Application number
PE2013001586A
Other languages
English (en)
Inventor
Ralf Anderskewitz
Domnic Martyres
Thorsten Oost
Wolfgang Rist
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140860(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20140860A1 publication Critical patent/PE20140860A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRAZOL DE FORMULA (Ia) O (Ib) DONDE: Ra Y Rb SON INDEPENDIENTEMENTE H, HIDROXI, ALCOXI C1-C6, ENTRE OTROS, O Ra Y Rb JUNTOS CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN GRUPO CARBONILO; Rc Y Rd SON INDEPENDIENTEMENTE H, HALOGENO, HALOALQUILO C1-6, ENTRE OTROS O Rc Y Rd JUNTOS CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN GRUPO CARBONILO, ENTRE OTROS; Y1, Y2, Y3, Y4 E Y5 SON INDEPENDIENTEMENTE N Y CRY, DONDE RY ES H, HIDROXI, CIANO, ENTRE OTROS; Z ES O, S, Y NRZ, DONDE RZ ES H, ALQUILO C1-C6 O BENCILO; R1 Y R2 ES INDEPENDIENTEMENTE H, FENILO, NAFTILO, ENTRE OTROS; n ES UN NUIMERO ENTERO ENTRE 0 A 3; R3 SI ESTA PRESENTE ES HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO (1-(2-FLUORO-4-[(1H-INDOL-2-CARBONIL)AMINO]BENCIL)-3,5-DIMETIL-1H-PIRAZOL-4-IL)ACETICO; ACIDO (1-{4-[(5-FLUORO-3-METILBENZOFURAN-2-CARBONIL)AMINO]BENCIL}-3,5-DIMETIL-1H-PIRAZOL-4-IL)ACETICO; ENTRE OTROS. REFERIDO ADEMAS A FORMULACIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS EN COMBINACION CON UNA O MAS SUSTANCIAS ACTIVAS TAL COMO BETAMIMETICOS, ANTICOLINERGICOS, CORTICOSTEROIDES, ENTRE OTROS
PE2013001586A 2011-01-24 2012-01-20 Compuestos de pirazol como antagonistas de crth2 PE20140860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24

Publications (1)

Publication Number Publication Date
PE20140860A1 true PE20140860A1 (es) 2014-07-20

Family

ID=43799503

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001586A PE20140860A1 (es) 2011-01-24 2012-01-20 Compuestos de pirazol como antagonistas de crth2

Country Status (36)

Country Link
US (1) US8759386B2 (es)
EP (1) EP2668181B1 (es)
JP (1) JP5695216B2 (es)
KR (2) KR101923365B1 (es)
CN (4) CN104628705B (es)
AP (1) AP3343A (es)
AR (1) AR084916A1 (es)
AU (1) AU2012210718B2 (es)
BR (1) BR112013017570B1 (es)
CA (1) CA2825458C (es)
CL (1) CL2013001945A1 (es)
CO (1) CO6801731A2 (es)
CY (1) CY1116012T1 (es)
DK (1) DK2668181T3 (es)
EA (1) EA022559B1 (es)
EC (1) ECSP13012832A (es)
ES (1) ES2529452T3 (es)
GE (1) GEP20156332B (es)
HK (3) HK1215247A1 (es)
HR (1) HRP20150069T1 (es)
IL (1) IL226920A (es)
MA (1) MA34838B1 (es)
MX (1) MX342830B (es)
MY (1) MY163012A (es)
PE (1) PE20140860A1 (es)
PH (2) PH12013501356A1 (es)
PL (1) PL2668181T3 (es)
PT (1) PT2668181E (es)
RS (1) RS53785B1 (es)
SG (1) SG192096A1 (es)
SI (1) SI2668181T1 (es)
TN (1) TN2013000280A1 (es)
TW (1) TWI527809B (es)
UA (1) UA109696C2 (es)
UY (1) UY33873A (es)
WO (1) WO2012101043A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為crth2拮抗劑之吡唑化合物
JP5999387B2 (ja) * 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
WO2014079803A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hairloss
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
JP2021523931A (ja) * 2018-03-23 2021-09-09 パラティン テクノロジーズ, インコーポレイテッド メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法
JP7458406B2 (ja) 2018-12-21 2024-03-29 セルジーン コーポレーション Ripk2のチエノピリジン阻害剤
WO2025009852A1 (ko) * 2023-07-03 2025-01-09 주식회사 이노보테라퓨틱스 신규한 피라졸 유도체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
CZ20021604A3 (cs) * 1999-11-10 2002-09-11 Takeda Chemical Industries, Ltd. Pětičlenné N-heterocyklické sloučeniny, farmaceutický přípravek a činidlo je obsahující a jejich použití
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
DE602004011966T2 (de) * 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
KR20070092297A (ko) * 2004-12-21 2007-09-12 데브젠 엔브이 Kv4 이온 채널 활성을 갖는 화합물
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
US20090149524A1 (en) 2006-06-06 2009-06-11 Paul John Beswick N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration
JP4469924B2 (ja) * 2006-11-27 2010-06-02 ファイザー・プロダクツ・インク ピラゾール類似体
NZ584351A (en) * 2007-09-25 2012-03-30 Actimis Pharmaceuticals Inc 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
EP2205569B1 (en) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthio pyrimidines as crth2 antagonists
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
US20110190227A1 (en) * 2008-07-03 2011-08-04 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
ES2545865T3 (es) * 2010-01-27 2015-09-16 Boehringer Ingelheim International Gmbh Compuestos de pirazol como antagonistas de CRTH2
WO2012013567A1 (en) * 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為crth2拮抗劑之吡唑化合物

Also Published As

Publication number Publication date
HRP20150069T1 (hr) 2015-02-27
TWI527809B (zh) 2016-04-01
TW201245184A (en) 2012-11-16
SI2668181T1 (sl) 2015-02-27
IL226920A (en) 2016-11-30
KR20140005931A (ko) 2014-01-15
HK1210467A1 (en) 2016-04-22
CN107011332A (zh) 2017-08-04
PL2668181T3 (pl) 2015-04-30
CL2013001945A1 (es) 2013-10-25
PT2668181E (pt) 2015-02-05
EA201300857A1 (ru) 2013-12-30
JP5695216B2 (ja) 2015-04-01
PH12013501356A1 (en) 2013-09-02
WO2012101043A1 (en) 2012-08-02
RS53785B1 (en) 2015-06-30
NZ611695A (en) 2015-04-24
BR112013017570A2 (pt) 2016-10-18
SG192096A1 (en) 2013-08-30
PH12018501531A1 (en) 2019-04-08
EP2668181A1 (en) 2013-12-04
CN107011332B (zh) 2020-03-13
ECSP13012832A (es) 2013-09-30
CO6801731A2 (es) 2013-11-29
KR102251939B1 (ko) 2021-05-14
ES2529452T3 (es) 2015-02-20
MA34838B1 (fr) 2014-01-02
EP2668181B1 (en) 2014-11-05
US20130023576A1 (en) 2013-01-24
GEP20156332B (en) 2015-07-27
MY163012A (en) 2017-07-31
TN2013000280A1 (en) 2014-11-10
US8759386B2 (en) 2014-06-24
UA109696C2 (xx) 2015-09-25
CY1116012T1 (el) 2017-01-25
MX342830B (es) 2016-10-14
JP2014502986A (ja) 2014-02-06
EA022559B1 (ru) 2016-01-29
CN104961732A (zh) 2015-10-07
MX2013008082A (es) 2013-09-13
CN104628705A (zh) 2015-05-20
DK2668181T3 (da) 2015-01-19
AU2012210718B2 (en) 2016-06-02
CN103339125A (zh) 2013-10-02
KR20180129962A (ko) 2018-12-05
AP2013006942A0 (en) 2013-06-30
AU2012210718A1 (en) 2013-07-04
KR101923365B1 (ko) 2018-11-30
BR112013017570B1 (pt) 2022-01-11
AR084916A1 (es) 2013-07-10
AP3343A (en) 2015-07-31
CA2825458C (en) 2021-01-26
UY33873A (es) 2012-07-31
HK1215247A1 (zh) 2016-08-19
HK1186183A1 (en) 2014-03-07
CA2825458A1 (en) 2012-08-02
CN104961732B (zh) 2017-07-11
CN104628705B (zh) 2017-04-12
CN103339125B (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
PE20140860A1 (es) Compuestos de pirazol como antagonistas de crth2
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
PA8828101A1 (es) Compuestos triazina como inhibidores mtor y quinasa p13
MX369096B (es) Variantes y composiciones que comprenden variantes con alta estabilidad en presencia de un agente quelante.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
TN2011000346A1 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CO6541606A2 (es) Espiroindolinona- pirrolidinas
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
MY173342A (en) Inhibitors of hepatitis c virus
MY150542A (en) Cmet inhibitors
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
CU20110109A7 (es) Nueva composición a base de ácido gamma-hidroxibutírico
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
AR054425A1 (es) Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
IN2014DN06169A (es)
CO6420337A2 (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
NZ620635A (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
ECSP12011862A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
AR071483A1 (es) Derivados de la 1,3- dihidro -2h - pirrolo (3,2-b) piridin-2- ona, su preparacion y sus aplicaciones en terapeutica

Legal Events

Date Code Title Description
FG Grant, registration